Phase 2 N=23 NHL16: Study For Newly Diagnosed Patients With Acute Lymphoblastic Lymphoma
Lymphoblastic Lymphoma
Primary: Probability of Event-free Survival (EFS) — 91.7; 71.4; 100; 86.96 percentage of event-free patients
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=84 G-CSF Versus G-CSF Plus GM-CSF for Stem Cell Mobilization in NHL Patients
Lymphoma
Primary: CD34+ Cells/kg in Blood Stem Cells — 7.5; 10.34 CD34+ cells/kg
Phase 2 N=22 AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSF
Multiple Myeloma · Lymphoma, Non-Hodgkin
Primary: Number of Participants in Overall Safety Summary of Treatment Emergent Adverse Events (TEAE) — 4; 8; 12; 4 participants
Phase 3 N=41 Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL
B-Cell Non Hodgkin Lymphoma
Primary: Phase 2: Percentage of Participants Who Achieved Complete Metabolic Response (CMR) — 22.0 Percentage of participants
Phase 4 N=61 Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 Kilograms
Non-Hodgkin's Lymphoma
Primary: Proportion of Patients Who Achieved at Least 5*10^6 Cluster of Differentiation 34+ (CD34+) Cells Per Kilogram (Cells/kg) — 60.0; 54.8 percentage of participants — p=0.395
Phase 1 N=7 FT596 With Rituximab as Relapse Prevention After Autologous HSCT for NHL
NHL · Non Hodgkin Lymphoma · Diffuse Large B Cell Lymphoma
Primary: Number of Participants Experiencing Dose Limiting Toxicity Events — 0; 0; 0 Participants
Phase 2 N=28 Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Stage II, III, or IV Follicular NHL
Lymphoma
Primary: Progression-free Survival at 1 Year — 38 percentage of participants
Phase 2 N=39 Chemotherapy With Monoclonal Antibody and Radioimmunotherapy for High-Risk B-Cell Non-Hodgkins Lymphoma
Lymphoma, B-Cell
Primary: 1 Year Progression-free Survival Rate — 0.74 percentage of participants
Phase 2 N=72 Safety and Efficacy of BKM120 in Relapsed and Refractory NHL
Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma
Primary: Overall Response Rate (ORR) and Disease Control Rate (DCR) Per Investigator at 6 Months (FAS) — 11.5; 22.7; 25.0; 30.8 percentage of participants
Phase 1 N=79 Study Evaluating CMC-544 In B-Cell Non-Hodgkin's Lymphoma
Lymphoma, B-Cell
Primary: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs) — 29; 49; 11; 15 participants